FindTrial
Sign In

Role of Immunohistochemistry in Chronic Myeloid Leukemia cases.

Expression of BCL6 and p53 in Chronic Myeloid Leukemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/04/024898
Enrollment
20
Registered
2020-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs

Interventions

None listed

Sponsors

Maulana Azad Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All newly diagnosed, untreated cases of Chronic Myeloid Leukemia more than 18 years of age.

Exclusion criteria

Exclusion criteria: All Chronic Myeloid Leukemia cases on treatment.

Design outcomes

Primary

MeasureTime frame
Expression of BCL6 and p53 in Bone Marrow BiopsyTimepoint: At time interval of 8 weeks for 1 year.—

Secondary

MeasureTime frame
Association of BCL6 and p53 expression with clinicohematological parametres and with quantitative BCR-ABL1 by real time quantitative RT-PCR.Timepoint: At interval of 8 weeks for one year.—

Countries

India

Contacts

Public ContactRakesh

Maulana Azad Medical College

mohanprerna@gmail.com9999952113

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026